Investment Analysts’ Recent Ratings Updates for Cullinan Therapeutics (CGEM)

Cullinan Therapeutics (NASDAQ: CGEM) has recently received a number of price target changes and ratings updates:

• 2/17/2026 – Cullinan Therapeutics is now covered by analysts at Citigroup Inc.. They set a “buy” rating and a $33.00 price target on the stock.
• 2/8/2026 – Cullinan Therapeutics was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 2/2/2026 – Cullinan Therapeutics is now covered by analysts at Guggenheim. They set a “buy” rating and a $30.00 price target on the stock.
• 2/2/2026 – Cullinan Therapeutics is now covered by analysts at Guggenheim. They set a “buy” rating and a $30.00 price target on the stock.
• 1/31/2026 – Cullinan Therapeutics was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 1/23/2026 – Cullinan Therapeutics was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 1/21/2026 – Cullinan Therapeutics was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating.
• 1/8/2026 – Cullinan Therapeutics had its price target raised by analysts at HC Wainwright from $26.00 to $27.00. They now have a “buy” rating on the stock.
• 1/8/2026 – Cullinan Therapeutics had its “overweight” rating reaffirmed by analysts at Morgan Stanley. They now have a $30.00 price target on the stock.
• 12/29/2025 – Cullinan Therapeutics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – Cullinan Therapeutics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.

Insider Buying and Selling at Cullinan Therapeutics

In related news, CEO Nadim Ahmed sold 9,922 shares of the stock in a transaction on Tuesday, December 23rd. The shares were sold at an average price of $10.01, for a total value of $99,319.22. Following the transaction, the chief executive officer directly owned 420,699 shares of the company’s stock, valued at $4,211,196.99. This trade represents a 2.30% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Jeffrey Alan Jones sold 4,632 shares of the business’s stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $9.67, for a total value of $44,791.44. Following the completion of the sale, the insider owned 169,532 shares of the company’s stock, valued at approximately $1,639,374.44. This represents a 2.66% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 33,836 shares of company stock valued at $361,087 over the last three months. 6.07% of the stock is currently owned by company insiders.

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.